Amgen Inc. (AMGN) Stock Score, Valuation & Financial Research
Amgen Inc. is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 41/100.
Quick answer for AMGN
Amgen Inc. currently has a Wall Street Score of 41/100. The stored market price is $379.55. Its financial score is 23/100. Its valuation score is 59/100. The latest WSS change is +3.6 points. These figures are a research snapshot, not a buy or sell recommendation.
What Amgen Inc. does
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult
AMGN financial snapshot
- Wall Street Score:
- 41/100
- Current price:
- $379.55
- Market capitalization:
- $204.85B
- Revenue:
- $38.13B
- Net income:
- $8.74B
- Free cash flow:
- $8.10B
- Cash:
- $13.99B
- Total debt:
- $57.30B
- EPS:
- 16.22
- P/E ratio:
- 23.4x
- Financial score:
- 23/100
- Valuation score:
- 59/100
- Revenue score:
- 30/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $8.10B, showing positive cash generation.
- The balance sheet shows $13.99B of cash versus $57.30B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +3.6 points: AMGN increased 3.6 points because Capital improved by 2 points, Valuation improved by 19.5 points, Buffett improved by 2.1 points.
What the numbers mean
Its current valuation score is 59/100, which Wall Street Score classifies as mixed within the model's valuation framework.
The financial score is 23/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research AMGN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.